Dasatinib reduces myelofibrosis by modulating pSTAT5 and NF-κB

Blood Cells Mol Dis. 2019 May:76:78-81. doi: 10.1016/j.bcmd.2019.02.005. Epub 2019 Feb 20.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Dasatinib / pharmacology*
  • Dasatinib / therapeutic use
  • Humans
  • NF-kappa B / drug effects
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / prevention & control
  • Protein Kinase Inhibitors
  • STAT5 Transcription Factor / drug effects

Substances

  • NF-kappa B
  • Protein Kinase Inhibitors
  • STAT5 Transcription Factor
  • Dasatinib